title: Effects of azacitidine on matrix metalloproteinase-9 in acute myeloid leukemia and myelodysplasia.
abstract: Matrix metalloprotease-9 (MMP9) plays a critical role in acute myeloid leukemia (AML) by increasing the invasive properties of malignant myeloblasts. The role of this enzyme in high-risk myelodysplastic diseases (MDS) and the effect of azacitidine on its expression in MDS and AML have not been studied in detail. In this work, we have analyzed the effect of different concentrations of azacitidine in two well-established, MDS-derived, acute myeloid leukemic cell lines: MOLM-13 and SKM-1. We have demonstrated that 1 μmol/L azacitidine decreases MMP9 DNA methylation levels and that this is correlated with a significant increase in messenger RNA expression in both cell lines. Surprisingly, changes in protein levels were minor. This paradoxic effect is explained by the drug-dependent induction of apoptosis that reduces the amount of active secreting cells. A balance between induced expression and apoptosis was established at an azacitidine concentration of 0.2 μmol/L in MOLM-13 cells. This dose significantly increased the invasive capacity of viable cells, as measured in the Matrigel assay. To evaluate the clinical relevance of this observation, we have examined the effect of azacitidine on MMP9 expression in bone marrow from five patients with MDS, with the finding that this drug significantly increased MMP9 protein levels in all analyzed patients after six cycles of treatment. Based on these results, we conclude that azacitidine increases MMP9 expression and may enhance invasiveness in vitro. Because all five patients relapsed, these findings might explain, at least partially, the clinical failure of the drug and the progression to a more aggressive disease.
authors.affiliation: Servicio de Hematología, Hospital Universitario Central de Asturias, Oviedo, Spain. teresa.bernal@sespa.princast.es
authors.forename: Teresa
authors.initials: T
authors.lastname: Bernal
authors.forename: Angela
authors.initials: A
authors.lastname: Moncada-Pazos
authors.forename: Clara
authors.initials: C
authors.lastname: Soria-Valles
authors.forename: Ana
authors.initials: A
authors.lastname: Gutiérrez-Fernández
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000754:Anemia, Refractory, with Excess of Blasts / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D000963:Antimetabolites / Q000009:adverse effects / Q000627:therapeutic use*; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001374:Azacitidine / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D002384:Catalysis / Q000187:drug effects; D045744:Cell Line, Tumor / Q000187:drug effects / Q000201:enzymology; D019175:DNA Methylation / Q000187:drug effects; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D004790:Enzyme Induction / Q000187:drug effects; D005260:Female; D006801:Humans; D007948:Leukemia, Monocytic, Acute / Q000473:pathology*; D015479:Leukemia, Myelomonocytic, Acute / Q000473:pathology*; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000096:biosynthesis* / Q000235:genetics; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000235:genetics; D016609:Neoplasms, Second Primary / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology; D011401:Promoter Regions, Genetic / Q000187:drug effects; D012306:Risk
chemical_list: D000963:Antimetabolites; D000964:Antimetabolites, Antineoplastic; D009363:Neoplasm Proteins; D020780:Matrix Metalloproteinase 9; D001374:Azacitidine